Equities

Ocular Therapeutix Inc

Ocular Therapeutix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.60
  • Today's Change-0.36 / -3.28%
  • Shares traded627.61k
  • 1 Year change+403.56%
  • Beta1.2204
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Ocular Therapeutix Inc have a median target of 16.00, with a high estimate of 22.00 and a low estimate of 11.00. The median estimate represents a 50.94% increase from the last price of 10.60.
High107.5%22.00
Med50.9%16.00
Low3.8%11.00

Earnings history & estimates in USD

On Aug 07, 2024, Ocular Therapeutix Inc reported 2nd quarter 2024 losses of -0.26 per share.
The next earnings announcement is expected on Nov 13, 2024.
Average growth rate-824.23%
Ocular Therapeutix Inc reported annual 2023 losses of -1.02 per share on Mar 11, 2024.
Average growth rate-230.12%
More ▼

Revenue history & estimates in USD

Ocular Therapeutix, Inc. had 2nd quarter 2024 revenues of 16.44m. This bettered the 15.82m consensus of the 7 analysts covering the company. This was 22.93% above the prior year's 2nd quarter results.
Average growth rate+2.14%
Ocular Therapeutix, Inc. had revenues for the full year 2023 of 58.44m. This was 13.49% above the prior year's results.
Average growth rate+123.40%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.